Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain

DC Field Value Language
dc.contributor.authorYoon, Do Heum-
dc.contributor.authorBin, Seong-Il-
dc.contributor.authorChan, Simon Kin-Cheong-
dc.contributor.authorChung, Chun Kee-
dc.contributor.authorIn, Yong-
dc.contributor.authorKim, Hyoungmin-
dc.contributor.authorLichauco, Juan Javier-
dc.contributor.authorMok, Chi Chiu-
dc.contributor.authorMoon, Young-Wan-
dc.contributor.authorNg, Tony Kwun-Tung-
dc.contributor.authorPenserga, Ester Gonzales-
dc.contributor.authorShin, Dong Ah-
dc.contributor.authorYou, Dora-
dc.contributor.authorMoon, Hanlim-
dc.identifier.citationBMC Musculoskeletal Disorders, 18(1):337ko_KR
dc.descriptionAEs: Adverse events; BS-11: Box Scale-11; CIs: Confidence intervals; EAPC: European Association for Palliative Care; EQ VAS: EQ-5D visual analogue scale; EQ-5D-3 L questionnaire: EuroQol Group 5-Dimension SelfReport Questionnaire-3 Level Version Survey; GSQA: Global Sleep Quality Assessment Scale; ITT: Intent-to-treat; LS: Least squares; NICE: National Institute for Health and Care Excellence; NSAIDs: Nonsteroidal antiinflammatory drugs; PP: Per-protocol; SD: Standard deviation; TDB: Transdermal buprenorphine; TEAEs: Treatment-emergent adverse eventsko_KR

We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in real-world setting in Asian patients with musculoskeletal pain.

This was an open-label study conducted in Hong Kong, Korea, and the Philippines between June 2013 and April 2015. Eligible patients fulfilled the following criteria: 18 to 80 years of age; clinical diagnosis of osteoarthritis, rheumatoid arthritis, low back pain, or joint/muscle pain; chronic non-malignant pain of moderate to severe intensity (Box-Scale-11 [BS-11] pain score ≥ 4), not adequately controlled with non-opioid analgesics and requiring an opioid for adequate analgesia; and no prior history of opioid treatment. Patients started with a 5 μg/h buprenorphine patch and were titrated as necessary to a maximum of 40 μg/h over a 6-week period to achieve optimal pain control. Patients continued treatment with the titrated dose for 11 weeks. The primary efficacy endpoint was the change in BS-11 pain scores. Other endpoints included patients sleep quality and quality of life as assessed by the 8-item Global Sleep Quality Assessment Scale (GSQA) questionnaire and the EuroQol Group 5-Dimension Self-Report Questionnaire-3 Level version (EQ-5D-3 L), respectively. Tolerability was assessed by collecting adverse events.

A total of 114 eligible patients were included in the analysis. The mean BS-11 score at baseline was 6.2 (SD 1.6). Following initiation of TDB, there was a statistically significant improvement in BS-11 score from baseline to visit 3 (least squares [LS] mean change: -2.27 [95% CI -2.66 to −1.87]), which was maintained till the end of the study (visit 7) (LS mean change: −2.64 [95% -3.05 to −2.23]) (p < 0.0001 for both). The proportion of patients who rated sleep quality as good increased from 14.0% at baseline to 26.9% at visit 6. By visit 6, the mean EQ VAS score increased by 7.7 units (SD 17.9). There were also significant improvements in patients levels of functioning for all EQ-5D-3 L dimensions from baseline at visit 6 (p < 0.05 for all). Seventy-eight percent of patients reported TEAEs and 22.8% of patients discontinued due to TEAEs. TEAEs were generally mild to moderate in intensity (96.5%).

TDB provides effective pain relief with an acceptable tolerability profile over the 11-week treatment period in Asian patients with chronic musculoskeletal pain. More studies are needed to examine the long-term efficacy and safety of TBD treatment in this patient population.
dc.description.sponsorshipThis study was funded by Mundipharma Pte Ltd., Singaporeko_KR
dc.publisherBioMed Centralko_KR
dc.subjectTransdermal buprenorphineko_KR
dc.subjectChronic non-malignant painko_KR
dc.subjectPain scoreko_KR
dc.subjectQuality of lifeko_KR
dc.subjectSleep qualityko_KR
dc.titleEffectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal painko_KR
dc.rights.holderThe Author(s).-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Neurosurgery (신경외과학전공)Journal Papers (저널논문_신경외과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.